Valuation: Evaxion A/S

Market Cap 25.65M 22.41M 20.68M 19.06M 35.93M 2.47B 36.73M 247M 97.23M 1.21B 96.31M 94.2M 4.16B P/E 2026 *
-76.9x
P/E 2027 * 76.9x
Enterprise Value 25.65M 22.41M 20.68M 19.06M 35.93M 2.47B 36.73M 247M 97.23M 1.21B 96.31M 94.2M 4.16B EV / Sales 2026 *
-
EV / Sales 2027 * 1.51x
Free-Float
76.93%
Yield 2026 *
-
Yield 2027 * -
1 day-1.44%
1 week-3.00%
Current month-0.81%
1 month-7.38%
3 months-30.90%
6 months-32.42%
Current year-35.53%
1 week 2.99
Extreme 2.99
3.25
1 month 2.99
Extreme 2.99
3.64
Current year 2.87
Extreme 2.871
5.48
1 year 2.45
Extreme 2.45
12.15
3 years 1.2
Extreme 1.2
69.1
5 years 1.2
Extreme 1.2
1,252
10 years 1.2
Extreme 1.2
1,252
Manager TitleAgeSince
Chief Executive Officer 59 24/11/2025
Corporate Officer/Principal 49 11/08/2008
Director of Finance/CFO 53 01/11/2024
Director TitleAgeSince
Chairman 58 25/11/2020
Director/Board Member 56 01/01/2018
Director/Board Member 68 25/05/2021
Date Insider Type Main position Quantity % Market Cap.
4/16/26 A Other

Director

2,376 0.0006%
3/18/26 A Other

Director

483,391 0.1159%
3/18/26 A Other

Chief Executive Officer

2,286,150 0.5482%
Change 5-day change 1-year change 3-year change Capi.($)
-1.44%-3.00%+16.04%-95.12% 25.65M
+3.90%-0.39%+376.72%+599.59% 39.58B
-1.70%+4.46%+7.46%+57.67% 34.69B
-2.01%-0.76%+26.35%-6.83% 34.42B
+0.06%+0.34%+2.32%+29.30% 27.11B
+0.46%-3.49% - - 16.21B
-0.04%-0.09%+68.48%+117.39% 15.36B
+1.12%+1.91%+15.90%+19.65% 14.05B
0.00%+1.36%+15.74%-30.62% 13.02B
-0.08%-3.01%+1,271.69%+649.69% 11.76B
Average +0.03%-0.27%+200.08%+148.97% 20.62B
Weighted average by Cap. +0.24%+0.36%+171.41%+187.38%

Financials

2026 *2027 *
Net sales - 16.95M 14.81M 13.67M 12.6M 23.74M 1.63B 24.27M 163M 64.25M 799M 63.65M 62.25M 2.75B
Net income -15.78M -13.79M -12.73M -11.73M -22.11M -1.52B -22.6M -152M -59.84M -744M -59.28M -57.97M -2.56B -1.12M -975K -899K -829K -1.56M -107M -1.6M -10.75M -4.23M -52.6M -4.19M -4.1M -181M
Net Debt - -
Logo Evaxion A/S
Evaxion A/S, formerly known as Evaxion Biotech A/S, is a Denmark-based clinical-stage biotechnology company, which specializes in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases. The Company decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.
Employees
46
Date Price Change Volume
17/07/26 $3.075 -1.44% 13,969
16/07/26 $3.120 +2.30% 16,880
15/07/26 $3.050 +0.66% 25,221
14/07/26 $3.030 +0.33% 22,014
13/07/26 $3.020 -4.73% 14,579
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
3.075USD
Average target price
11.25USD
Spread / Average Target
+265.85%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EVAX Stock